Stakeholder Insight: Non-Small Cell Lung Cancer - The Need For Greater Product Differentiation In An Increasingly Crowded Market - Biologics Market Research

Stakeholder Insight: Non-Small Cell Lung Cancer - The Need For Greater Product Differentiation In An Increasingly Crowded Market
Published Date: November 2006
Published By: Datamonitor
Order Code: R313-18111
Price: $15200 Online Download
$30400 Global Site License
Introduction
NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months.
Scope of this report
Diagnosis patterns of NSCLC including stage distribution and extent of resectability based on a survey of 180 physicians across the seven markets
Analysis of treatment modalities and regimens according to Datamonitor's primary research data
Ranking of the greatest areas of unmet need within the NSCLC market
Physician ratings of key pipeline NSCLC candidates and the likelihood of future scenarios occurring
Research and analysis highlights
According to Datamonitor's research, one-third of all non-resectable advanced NSCLC patients receive no drug therapy. The development of agents suitable for elderly and poor performance status patients, inducing those with existing comorbidities, provides significant commercial opportunity
While platinum-based regimens form the mainstay of first-line NSCLC treatment, Datamonitor's research reveals that there is little to differentiate between the available cytotoxic regimens, indicating that the efficacy of cytotoxics may have reached a plateau.
Avastin has become the first FDA approved MTT for the first-line treatment of NSCLC, labeled for administration in combination with carboplatin and paclitaxel. As more MTTs emerge from the developmental pipeline and targeted patient selection becomes more frequent, the treatment of NSCLC will undergo a transformation
Key reasons to read this report
Identify the key factors that influence prescribing patterns for NSCLC pharmacotherapy
Examine the significant unmet needs in the NSCLC market and identify opportunities for new product development
Enhance your commercial positioning through an increased understanding of NSCLC market dynamics